Gliklazid (Uzbek Wikipedia)

Analysis of information sources in references of the Wikipedia article "Gliklazid" in Uzbek language version.

refsWebsite

Global rank Uzbek rank

4^th place

7^th place

2^nd place

3^rd place

399^th place

440^th place

3,823^rd place

7,995^th place

1^st place

6^th place

8^th place

low place

3,327^th place

archive.org

Rieutord, A; Stupans, I; Shenfield, GM; Gross, AS (1995). „Gliclazide hydroxylation by rat liver microsomes“. Xenobiotica. 25-jild, № 12. 1345–54-bet. doi:10.3109/00498259509061922. PMID 8719909.
Elliot, David J.; Lewis, Benjamin C.; Gillam, Elizabeth M. J.; Birkett, Donald J.; Gross, Annette S.; Miners, John O.; Miners, JO (2007). „Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination“. British Journal of Clinical Pharmacology. 64-jild, № 4. 450–7-bet. doi:10.1111/j.1365-2125.2007.02943.x. PMC 2048545. PMID 17517049.
Zhang, Yifan; Si, Dayong; Chen, Xiaoyan; Lin, Nan; Guo, Yingjie; Zhou, Hui; Zhong, Dafang (2007). „Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects“. British Journal of Clinical Pharmacology. 64-jild, № 1. 67–74-bet. doi:10.1111/j.1365-2125.2007.02846.x. PMC 2000619. PMID 17298483.
Xu, H; Williams, K M; Liauw, W S; Murray, M; Day, R O; McLachlan, A J (2009). „Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide“. British Journal of Pharmacology. 153-jild, № 7. 1579–86-bet. doi:10.1038/sj.bjp.0707685. PMC 2437900. PMID 18204476.

, arxivsana= parametri ham koʻrsatilishi zarur. „Gliclazide - Drugs.com“. www.drugs.com.

(Wayback Machine saytida 2022-09-22 sanasida [https://web.archive.org/web/20220922022052/https://www.medicines.org.uk/emc/medicine/31089 arxivlangan) „Gliclazide Accord-UK 30mg Prolonged-release Tablets - Summary of Product Characteristics (SmPC)“]. (emc) (12-fevral 2021-yil). 2022-yil 22-sentyabrda asl nusxadan arxivlangan. Qaraldi: 2022-yil 11-iyun.

Rieutord, A; Stupans, I; Shenfield, GM; Gross, AS (1995). „Gliclazide hydroxylation by rat liver microsomes“. Xenobiotica. 25-jild, № 12. 1345–54-bet. doi:10.3109/00498259509061922. PMID 8719909.
Elliot, David J.; Lewis, Benjamin C.; Gillam, Elizabeth M. J.; Birkett, Donald J.; Gross, Annette S.; Miners, John O.; Miners, JO (2007). „Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination“. British Journal of Clinical Pharmacology. 64-jild, № 4. 450–7-bet. doi:10.1111/j.1365-2125.2007.02943.x. PMC 2048545. PMID 17517049.
Zhang, Yifan; Si, Dayong; Chen, Xiaoyan; Lin, Nan; Guo, Yingjie; Zhou, Hui; Zhong, Dafang (2007). „Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects“. British Journal of Clinical Pharmacology. 64-jild, № 1. 67–74-bet. doi:10.1111/j.1365-2125.2007.02846.x. PMC 2000619. PMID 17298483.
Xu, H; Williams, K M; Liauw, W S; Murray, M; Day, R O; McLachlan, A J (2009). „Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide“. British Journal of Pharmacology. 153-jild, № 7. 1579–86-bet. doi:10.1038/sj.bjp.0707685. PMC 2437900. PMID 18204476.

Elliot, David J.; Lewis, Benjamin C.; Gillam, Elizabeth M. J.; Birkett, Donald J.; Gross, Annette S.; Miners, John O.; Miners, JO (2007). „Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination“. British Journal of Clinical Pharmacology. 64-jild, № 4. 450–7-bet. doi:10.1111/j.1365-2125.2007.02943.x. PMC 2048545. PMID 17517049.
Zhang, Yifan; Si, Dayong; Chen, Xiaoyan; Lin, Nan; Guo, Yingjie; Zhou, Hui; Zhong, Dafang (2007). „Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects“. British Journal of Clinical Pharmacology. 64-jild, № 1. 67–74-bet. doi:10.1111/j.1365-2125.2007.02846.x. PMC 2000619. PMID 17298483.
Xu, H; Williams, K M; Liauw, W S; Murray, M; Day, R O; McLachlan, A J (2009). „Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide“. British Journal of Pharmacology. 153-jild, № 7. 1579–86-bet. doi:10.1038/sj.bjp.0707685. PMC 2437900. PMID 18204476.

(Wayback Machine saytida 2022-09-22 sanasida [https://web.archive.org/web/20220922022052/https://www.medicines.org.uk/emc/medicine/31089 arxivlangan) „Gliclazide Accord-UK 30mg Prolonged-release Tablets - Summary of Product Characteristics (SmPC)“]. (emc) (12-fevral 2021-yil). 2022-yil 22-sentyabrda asl nusxadan arxivlangan. Qaraldi: 2022-yil 11-iyun.